DK0654267T3 - Carcinostatisk middel til hormonterapi indeholdende dienogest som aktiv komponent - Google Patents

Carcinostatisk middel til hormonterapi indeholdende dienogest som aktiv komponent

Info

Publication number
DK0654267T3
DK0654267T3 DK94118050T DK94118050T DK0654267T3 DK 0654267 T3 DK0654267 T3 DK 0654267T3 DK 94118050 T DK94118050 T DK 94118050T DK 94118050 T DK94118050 T DK 94118050T DK 0654267 T3 DK0654267 T3 DK 0654267T3
Authority
DK
Denmark
Prior art keywords
active component
hormone therapy
carcinostatic agent
therapy containing
containing dienogest
Prior art date
Application number
DK94118050T
Other languages
Danish (da)
English (en)
Inventor
Masaomi Obata
Masami Sato
Yukio Katsuki
Yasunori Shibutani
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Application granted granted Critical
Publication of DK0654267T3 publication Critical patent/DK0654267T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94118050T 1993-11-19 1994-11-15 Carcinostatisk middel til hormonterapi indeholdende dienogest som aktiv komponent DK0654267T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29082393 1993-11-19

Publications (1)

Publication Number Publication Date
DK0654267T3 true DK0654267T3 (da) 2002-05-13

Family

ID=17760949

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94118050T DK0654267T3 (da) 1993-11-19 1994-11-15 Carcinostatisk middel til hormonterapi indeholdende dienogest som aktiv komponent

Country Status (9)

Country Link
US (1) US5652231A (de)
EP (1) EP0654267B1 (de)
AT (1) ATE215826T1 (de)
AU (1) AU683098B2 (de)
CA (1) CA2136140C (de)
DE (1) DE69430356T2 (de)
DK (1) DK0654267T3 (de)
ES (1) ES2176218T3 (de)
PT (1) PT654267E (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274573B1 (en) * 1997-10-17 2001-08-14 Mochida Pharmaceutical Co., Ltd. Method of treatment for uterine leiomyoma
WO1999033857A1 (fr) * 1997-12-26 1999-07-08 Mochida Pharmaceutical Co., Ltd. Inhibiteur de cytokine d'osteoresorption contenant du dienogest en tant que principe actif
WO1999033856A1 (fr) * 1997-12-26 1999-07-08 Mochida Pharmaceutical Co., Ltd. Inhibiteur de neoformation de vaisseaux sanguins contenant du dienogest en tant que principe actif
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE19908762A1 (de) * 1999-02-18 2000-08-31 Jenapharm Gmbh Verwendung von Dienogest in hoher Dosierung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718872A1 (de) * 1976-06-14 1977-12-22 Jenapharm Veb Verfahren zur herstellung von neuen gona-4,9(10)-dienen
JPS6372627A (ja) * 1986-09-17 1988-04-02 Mitsubishi Kasei Corp 子宮内膜症治療薬
JPS643121A (en) * 1987-06-25 1989-01-06 Mitsubishi Kasei Corp Remedy for endometriosis
JPS643122A (en) * 1987-06-25 1989-01-06 Mitsubishi Kasei Corp Remedy for endometriosis
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity

Also Published As

Publication number Publication date
ATE215826T1 (de) 2002-04-15
AU7888394A (en) 1995-05-25
CA2136140A1 (en) 1995-05-20
DE69430356D1 (de) 2002-05-16
EP0654267A1 (de) 1995-05-24
ES2176218T3 (es) 2002-12-01
DE69430356T2 (de) 2002-08-14
EP0654267B1 (de) 2002-04-10
PT654267E (pt) 2002-09-30
AU683098B2 (en) 1997-10-30
CA2136140C (en) 2007-10-30
US5652231A (en) 1997-07-29

Similar Documents

Publication Publication Date Title
EP1033981A4 (de) Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln
DE69527509T2 (de) Hydrogelformulierung mit gesteuerter freisetzung
AU5217493A (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
MY118151A (en) Pharmaceutical formulations containing voriconazole.
DE69327432T2 (de) Heilmittel für wunden und hämorrhoiden
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
FI951856A (fi) Farmaseuttinen koostumus osteoporoosin hoitamiseksi
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
EP0754457A4 (de) Wirkstoff gegen fettsucht
KR960702320A (ko) 감마 인터페론의 안정한 액체 조성물 (Stable Liquid Compositions of Gamma Interferon)
EP0620004A4 (de) Medizinische zusammensetzung.
GR3015014T3 (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts.
DK0654267T3 (da) Carcinostatisk middel til hormonterapi indeholdende dienogest som aktiv komponent
MX9504023A (es) Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
EP0869786A4 (de) Arzneistoffe
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
ATE169819T1 (de) (-)-metrifonat enthaltendes arzneimittel
AU691674B2 (en) Preventive and remedy for diarrhea
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
KR930019216A (ko) 종양 치료제
Grachev et al. Decrease of toxic effects of aminothiol radiation-protective agents and increase of chemical protection action against ionizing radiation by the use of unithiol
IT1240853B (it) Composizione farmaceutica atta alla somministrazione intranasale comprendente calcitonina e una acil-carnitina
DK0608648T3 (da) Højdoserede vitamin A-præparater